Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Adverum Biotechnologies ( (ADVM) ) just unveiled an update.
Adverum Biotechnologies reported encouraging results from its LUNA Phase 2 and OPTIC extension trials, showcasing its promising gene therapy candidate, Ixo-vec, for treating wet age-related macular degeneration (AMD). The trials demonstrated significant reductions in anti-VEGF injection burdens and maintained visual and anatomical outcomes, highlighting Ixo-vec’s potential to transform the treatment landscape for wet AMD. With robust patient preference and a favorable safety profile, Ixo-vec is poised for further clinical success as it progresses towards Phase 3 trials.
See more data about ADVM stock on TipRanks’ Stock Analysis page.